Sarcoma Awareness Month: An update on the STRASS 2 trial

Associate Professor David Gyorki hosts a special webinar on progress in treatments for rare retroperitoneal sarcoma.

The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients with rare retroperitoneal sarcoma, It is a pan-European study with a transatlantic collaboration with multiple specialized sarcoma centres in Australia, Canada and North America.

This webinar will:

• Set out the non-standardised treatment patient are currently getting
• Explore the potential advantages/dis-advantages of neo-adjuvant therapy in sarcoma
• Learn the design and key findings of the STRASS and STRASS II trials to date
• Discuss the potential impact of the STRASS II trial in the management of sarcoma patients.

Speakers

• Dr Denise Caruso, CEO of ANZSA
• Associate Professor Peter Grimison, Medical Oncologist, Chris O'Brien Lifehouse
• Associate Professor David Gyorki, VCCC Alliance Research & Education Lead; Consultant Surgeon, Peter MacCallum Cancer Centre; Consultant Surgeon, Austin Health
• Karen Lurati (patient/consumer)

Presented in partnership with the Australia New Zealand Sarcoma Association

Associate Professor David Gyorki

Associate Professor David Gyorki is a consultant surgical oncologist at the Peter MacCallum Cancer Centre, specialising in the management of patients with melanoma and soft tissue sarcoma. He is also the Research and Education Lead in Melanoma and Skin Cancer at the Victorian Comprehensive Cancer Centre.

Thursday 28 July
5pm - 6pm

This virtual event will be hosted via Zoom. Zoom is accessible on your computer, tablet or phone via the Zoom app. If you have any issues with this platform on your device, please visit the Zoom support site. Alternatively please contact your IT administrator.